CARDINAL is a Phase 2/3 clinical study evaluating the safety and effectiveness of bardoxolone methyl (an oral investigational drug) for the treatment of Alport syndrome
- Diagnosis of Alports Syndrome (if genetic testing is needed, the cost is covered)
- Receiving Dialysis
- Renal Transplant Recipient
Study participation will last 2 years, and include two screening visits, baseline visit, and a total of 16 follow-up visits and 6 scheduled phone calls.
Study visits at Tufts Medical center will include surveys of symptoms, a blood draw, and urine collection
The screening visit will also include an Echo and EKG and a genetic test (if needed). The week 12 visit will included 3 timed blood draws
After the baseline visit, patients will be assigned to the Bardoloxone group or placebo group, and will increase dose gradually to maximum dose.